ASCO 2026: Dana-Farber Phase 2 Trial — CAR-T Achieves 100% MRD-Negativity in High-Risk Smoldering Multiple Myeloma

At ASCO 2026, Dana-Farber Cancer Institute researchers presented Phase 2 trial data showing BCMA-targeted CAR-T cell therapy achieves deep and durable responses in patients with high-risk smoldering multiple myeloma (SMM) — a pre-malignant condition that progresses to active multiple myeloma in approximately 50% of patients within 5 years under traditional watch-and-wait management. All 20 evaluable patients in the trial achieved minimal residual disease (MRD) negativity — meaning no detectable cancer cells in bone marrow — within 2 months of CAR-T infusion, and the majority remained MRD-negative at a median follow-up of 15.3 months. This is a conceptually significant finding: deploying CAR-T therapy at the smoldering (pre-active) disease stage, before patients have symptomatic organ damage requiring urgent treatment, may allow deeper and longer-lasting remissions than treating established active myeloma. The trial represents a paradigm shift from treating myeloma as purely a reactive intervention to considering curative-intent early CAR-T intervention. If MRD-negative status translates into delayed or prevented progression to active myeloma in long-term follow-up, this approach could fundamentally change the management of high-risk SMM. Longer follow-up to assess whether MRD negativity translates to progression-free and overall survival benefit is ongoing.